Compare · PROF vs SYK
PROF vs SYK
Side-by-side comparison of Profound Medical Corp. (PROF) and Stryker Corporation (SYK): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both PROF and SYK operate in Medical/Dental Instruments (Health Care), so they compete in similar markets.
- SYK is the larger of the two at $129.09B, about 484.7x PROF ($266.4M).
- Over the past year, PROF is up 27.2% and SYK is down 16.0% - PROF leads by 43.1 points.
- PROF has been more active in the news (7 items in the past 4 weeks vs 2 for SYK).
- SYK has more recent analyst coverage (25 ratings vs 8 for PROF).
- Company
- Profound Medical Corp.
- Stryker Corporation
- Price
- $7.30+0.41%
- $336.70+1.92%
- Market cap
- $266.4M
- $129.09B
- 1M return
- +15.51%
- +6.50%
- 1Y return
- +27.18%
- -15.96%
- Industry
- Medical/Dental Instruments
- Medical/Dental Instruments
- Exchange
- NASDAQ
- NYSE
- IPO
- News (4w)
- 7
- 2
- Recent ratings
- 8
- 25
Profound Medical Corp.
Profound Medical Corp., together with its subsidiaries, operates as a medical technology company that develops magnetic resonance guided ablation procedures for treatment of prostate disease, uterine fibroids, and palliative pain treatment in Canada, Germany, the United States, and Finland. Its lead product TULSA-PRO system used for magnetic resonance imaging scanner in hospitals and treatment facilities. The company also offers Sonalleve, a therapeutic platform for the treatment of uterine fibroids and palliative pain relief associated with metastases in bone, as well as non-invasive treatment of uterine fibroids. Profound Medical Corp. is headquartered in Mississauga, Canada.
Stryker Corporation
Stryker Corporation operates as a medical technology company. The company operates through three segments: Orthopaedics, MedSurg, and Neurotechnology and Spine. The Orthopaedics segment provides implants for use in hip and knee joint replacements, and trauma and extremities surgeries. The MedSurg segment offers surgical equipment and surgical navigation systems, endoscopic and communications systems, patient handling, emergency medical equipment and intensive care disposable products, reprocessed and remanufactured medical devices, and other medical device products that are used in various medical specialties. The Neurotechnology and Spine segment provides neurotechnology products, which include products used for minimally invasive endovascular techniques; products for brain and open skull based surgical procedures; orthobiologic and biosurgery products, such as synthetic bone grafts and vertebral augmentation products; and minimally invasive products for the treatment of acute ischemic and hemorrhagic stroke. This segment also offers spinal implant products comprising cervical, thoracolumbar, and interbody systems that are used in spinal injury, deformity, and degenerative therapies. The company sells its products to doctors, hospitals, and other healthcare facilities through company-owned subsidiaries and branches, as well as third-party dealers and distributors in approximately 75 countries. Stryker Corporation was founded in 1941 and is headquartered in Kalamazoo, Michigan.
Latest PROF
- Profound Medical upgraded by Raymond James with a new price target
- Profound Medical Corp. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits
- Robotic Radical Prostatectomy Comes Up ‘Short’ in CAPTAIN Trial
- Profound Medical Corp. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits
- Profound Medical to Release Second Quarter 2026 Financial Results on August 6th – Conference Call to Follow
- Profound Medical Corp. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits
- Profound Medical: Autonomous Robotics and Incisionless Surgery to Have Exceptional Presence at SRS2026
- SEC Form EFFECT filed by Profound Medical Corp.
- Profound Medical Corp. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits
- Telix Announces Collaborations to Explore PSMA-PET Imaging in Emerging Prostate Cancer Treatment Approaches
Latest SYK
- Stryker expands Mako robotics portfolio with full market release of Mako RPS
- BMO Capital Markets initiated coverage on Stryker with a new price target
- Stryker to announce second quarter 2026 financial results
- Stryker Corporation filed SEC Form 8-K: Other Events, Financial Statements and Exhibits
- Stryker partners with professional golfer Shane Lowry to spotlight the caregiver journey in joint replacement
- Fresh Off Its Nasdaq Debut, a Regenerative-Medicine Upstart Is Stacking Its Board With Big-Pharma Firepower
- President and COO Stiles Spencer S gifted 1,607 shares, decreasing direct ownership by 2% to 76,027 units (SEC Form 4)
- Stryker launches TPX HD® power tool, supporting demanding orthopaedic procedures
- VP, Chief Legal Officer Fletcher Robert S sold $1,394,409 worth of shares (4,544 units at $306.87) as part of a pre-agreed trading plan, decreasing direct ownership by 30% to 10,582 units (SEC Form 4)
- Director Stryker Ronda E sold $96,792,669 worth of shares (310,000 units at $312.23) (SEC Form 4)